Abstract
Overview
Introduction
Datamonitor expects the antihypertensive market to exceed $50bn by 2014 across
the seven major markets, with novel treatments and the market-leading ARBs
delivering much of this value. However, significant hurdles exist, and
pharmaceutical companies need to be savvy regarding marketing and pricing
structures for their products, as only the most cunning and aggressive
companies look set to survive
Scope
- Event-driven sales forecasts, for the period 2005-14, for the US, Japan,
France, Germany, Italy, Spain and the UK, along with a global overview
- Discussion of individual products in four main classes; beta blockers
(BBs), CCBs, ACE inhibitors and the ARBs
- Profiles of the country and market specific issues which will impact
future sales in the market including generic erosion and new product launches
- Commercial impact case studies on R&D innovation, clinical trial data and
European healthcare reform are included in the analysis
Report Highlights
The ARBs are now the most prescribed class of antihypertensives, as aggressive
marketing and premium-pricing enables manufacturers to deliver strong growth
in a highly genericized market. Post-2009, however, the value of the ARB class
is set to flatten on the back of generic erosion and indication expansion for
the ARBs as a class
In order for companies to achieve and maintain growth in this sector,
companies need to be savvy regarding the impact of healthcare reform across
the globe, particularly in Europe, with marketers who are charged with selling
drugs across the EU needing to challenge the attitude that Europe is one,
uniform, market like the US and Japan
Novartis' SPP100 (aliskiren) looks set to become the first innovative
treatment for hypertension in over a decade. However, due to concerns
regarding premium-pricing and similar efficacy compared to the ARBs, market
penetration is expected to be slow in the short-term until strong
cardiovascular outcome data for the class becomes available
Reasons to Purchase
- View independent, event-driven forecasts for key antihypertensive products
and classes across the seven major markets
- Gain insight of the antihypertensive market via Datamonitor analyses,
using up to date thought leader opinions and gold-standard IMS Health sales
data
- Identify the potential impact of clinical trial results, EU healthcare
reform and new product launches on the antihypertensive market
| 
View Cart
